Phase I trial of Intraperitoneal (IP) administration of a measles virus (MV) derivative expressing the human carcinoembryonic antigen (CEA) in recurrent ovarian cancer (OvCa)

被引：4
|
作者：
Galanis, E. [1 ]
Hartmann, L. C. [1 ]
Cliby, W. [1 ]
Peethambaram, P. P. [1 ]
Long, H. J. [1 ]
Kaur, J. S. [1 ]
Haluska, P., Jr. [1 ]
Sloan, J. A. [1 ]
Peng, K. [1 ]
Russell, S. J. [1 ]
机构：
[1] Mayo Clin, Coll Med, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.5538
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5538
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase I clinical trial of autologous T cells bearing fully humanized chimeric antigen receptors targeting mesothelin with both intravenous administration and local delivery with or without lymphodepletion in mesothelin-expressing cancers, including ovarian cancer
    Tanyi, Janos
    Haas, Andrew
    Aggarwal, Charu
    O'Hara, Mark
    Fraietta, Joe
    Golden, Ryan
    Hwang, Wei-Ting
    Young, Regina
    Shea, Kim-Marie
    Dowd, Emily
    Marshall, Amy
    Barber-Rotenberg, Julie
    Cosey, Angela
    Jadlowsky, Julie
    Chew, Anne
    Sheppard, Neil
    Albelda, Steven
    June, Carl
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S291 - S292
  • [42] Phase I trial of tandem intravenous and intraperitoneal delivery of IL-12 armored CAR T cells targeting MUC16 in patients with recurrent high-grade serous ovarian cancer
    Gormally, Michael
    Klebanoff, Christopher
    O'Cearbhaill, Roisin
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A506 - A507
  • [43] A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer
    Mythili Koneru
    Roisin O’Cearbhaill
    Swati Pendharkar
    David R Spriggs
    Renier J Brentjens
    Journal of Translational Medicine, 13
  • [44] A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer
    Koneru, Mythili
    O'Cearbhaill, Roisin
    Pendharkar, Swati
    Spriggs, David R.
    Brentjens, Renier J.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2015, 13
  • [45] Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer
    Rochlitz, C
    Figlin, R
    Squiban, P
    Salzberg, M
    Pless, M
    Herrmann, R
    Tartour, E
    Zhao, YX
    Bizouarne, N
    Baudin, M
    Acres, B
    JOURNAL OF GENE MEDICINE, 2003, 5 (08): : 690 - 699
  • [46] A first-in-human dose escalation and dose-finding phase I/II trial of IMAB027 in patients with recurrent advanced ovarian cancer (GM-IMAB-002-01)
    Jaeger, Dirk
    Sahin, Ugur
    Tureci, Oezlem
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [47] A phase I/IIa, open label, clinical trial evaluating the safety and efficacy of autologous T cells expressing enhanced TCRs specific for NY-ESO-1 in patients with recurrent or treatment refractory ovarian cancer (NCT01567891).
    Odunsi, Kunle
    Cristea, Mihaela C.
    Dorigo, Oliver
    Jazaeri, Amir A.
    Slomovitz, Brian M.
    Chagin, Karen
    Van Winkle, Erin
    Kari, Gabor
    Iyengar, Malini
    Norry, Elliot
    Bartlett-Pandite, Arundathy N.
    Amado, Rafael G.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [48] A phase I, dose escalation trial to assess the safety and biological activity of recombinant human interleukin-18 (SB-485232) in combination with pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer
    Simpkins, Fiona
    Flores, Aurea M.
    Chu, Christina
    Lucci, Joseph A.
    Berek, Jonathan S.
    Coukos, George
    Bauman, John W.
    Murray, Sharon Cornell
    Struemper, Herbert
    Germaschewski, Fiona
    Jonak, Zdenka
    Gardner, Olivia S.
    Toso, John F.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [49] Phase I trial of intraperitoneal injection of the E1B-55-kd-Gene -: Deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer
    Vasey, PA
    Shulman, LN
    Campos, S
    Davis, J
    Gore, M
    Johnston, S
    Kirn, DH
    O'Neill, V
    Siddiqui, N
    Seiden, MV
    Kaye, SB
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (06) : 1562 - 1569
  • [50] A phase I clinical trial of autologous chimeric antigen receptor (CAR) T cells genetically engineered to secrete IL-12 and to target the MUC16ecto antigen in patients (pts) with MUC16ecto+recurrent high-grade serous ovarian cancer (HGSOC)
    O'Cearbhaill, R. E.
    Park, J. H.
    Halton, E. F.
    Diamonte, C. R.
    Mead, E.
    Lakhman, Y.
    Kane, P.
    Riviere, I. C.
    Brentjens, R. J.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 42 - 42
12345